FDA approves Galderma's Nemluvio as the first monoclonal antibody for prurigo nodularis.

The FDA approved Galderma's Nemluvio (nemolizumab) as the 1st monoclonal antibody for adults with prurigo nodularis, a chronic skin condition affecting 181,000 US individuals. Nemluvio targets IL-31 signaling and demonstrated significant improvements in itch and nodules at Week 16, with early reductions in itch at Week 4. The treatment is generally well-tolerated and has a consistent safety profile.